Visual Acuity Outcome over Time in Non-Infectious Uveitis

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

Research output: Contribution to journalArticle

Abstract

Introduction: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population. Methods: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up. Results: Patients were a median of 41 years old, 65% female, and 73% white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each P <.001), then remained stable, except posterior uveitis mean VA worsened to initial levels. Conclusion: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Uveitis
Visual Acuity
Panuveitis
Posterior Uveitis
Tertiary Healthcare
Outcome Assessment (Health Care)

Keywords

  • inverse probability of censoring weighting
  • Uveitis
  • Visual acuity

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Cite this

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group (Accepted/In press). Visual Acuity Outcome over Time in Non-Infectious Uveitis. Ocular Immunology and Inflammation. https://doi.org/10.1080/09273948.2019.1687733

Visual Acuity Outcome over Time in Non-Infectious Uveitis. / Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group.

In: Ocular Immunology and Inflammation, 01.01.2019.

Research output: Contribution to journalArticle

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. Visual Acuity Outcome over Time in Non-Infectious Uveitis. Ocular Immunology and Inflammation. 2019 Jan 1. https://doi.org/10.1080/09273948.2019.1687733
Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group. / Visual Acuity Outcome over Time in Non-Infectious Uveitis. In: Ocular Immunology and Inflammation. 2019.
@article{0da12e832f114255ae7d5e68550aa2c3,
title = "Visual Acuity Outcome over Time in Non-Infectious Uveitis",
abstract = "Introduction: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population. Methods: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up. Results: Patients were a median of 41 years old, 65{\%} female, and 73{\%} white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each P <.001), then remained stable, except posterior uveitis mean VA worsened to initial levels. Conclusion: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.",
keywords = "inverse probability of censoring weighting, Uveitis, Visual acuity",
author = "{Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group} and Maxwell Pistilli and Joffe, {Marshall M.} and Gangaputra, {Sapna S.} and Pujari, {Siddharth S.} and Jabs, {Douglas A.} and Levy-Clarke, {Grace A.} and Nussenblatt, {Robert B.} and Rosenbaum, {James T.} and Sen, {H. Nida} and Suhler, {Eric B.} and Thorne, {Jennifer E.} and Bhatt, {Nirali P.} and Foster, {C. Stephen} and Hosne Begum and Fitzgerald, {Tonetta D.} and Dreger, {Kurt A.} and Altaweel, {Michael M.} and Holbrook, {Janet T.} and Kempen, {John H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/09273948.2019.1687733",
language = "English (US)",
journal = "Ocular Immunology and Inflammation",
issn = "0927-3948",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Visual Acuity Outcome over Time in Non-Infectious Uveitis

AU - Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group

AU - Pistilli, Maxwell

AU - Joffe, Marshall M.

AU - Gangaputra, Sapna S.

AU - Pujari, Siddharth S.

AU - Jabs, Douglas A.

AU - Levy-Clarke, Grace A.

AU - Nussenblatt, Robert B.

AU - Rosenbaum, James T.

AU - Sen, H. Nida

AU - Suhler, Eric B.

AU - Thorne, Jennifer E.

AU - Bhatt, Nirali P.

AU - Foster, C. Stephen

AU - Begum, Hosne

AU - Fitzgerald, Tonetta D.

AU - Dreger, Kurt A.

AU - Altaweel, Michael M.

AU - Holbrook, Janet T.

AU - Kempen, John H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population. Methods: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up. Results: Patients were a median of 41 years old, 65% female, and 73% white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each P <.001), then remained stable, except posterior uveitis mean VA worsened to initial levels. Conclusion: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.

AB - Introduction: We evaluated visual acuity (VA) over 5 years in a subspecialty noninfectious uveitis population. Methods: Retrospective data from 5,530 noninfectious uveitis patients with anterior, intermediate, posterior or panuveitis were abstracted by expert reviewers. Mean VA was calculated using inverse probability of censoring weighting to account for losses to follow-up. Results: Patients were a median of 41 years old, 65% female, and 73% white. Initial mean VA was worse among panuveitis (20/84) than posterior (20/64), intermediate (20/47), and anterior (20/37) uveitides. On average, mean VA improved by 0.62, 0.51, 0.37, and 0.26 logMAR-equivalent lines over 2 years, respectively (each P <.001), then remained stable, except posterior uveitis mean VA worsened to initial levels. Conclusion: Mean VA of uveitic eyes improved and, typically, improvement was sustained under uveitis subspecialty care. Because VA tends to improve under tertiary care, mean VA change appears a better outcome for clinical studies than time-to-loss of VA.

KW - inverse probability of censoring weighting

KW - Uveitis

KW - Visual acuity

UR - http://www.scopus.com/inward/record.url?scp=85076423607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076423607&partnerID=8YFLogxK

U2 - 10.1080/09273948.2019.1687733

DO - 10.1080/09273948.2019.1687733

M3 - Article

C2 - 31821051

AN - SCOPUS:85076423607

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

SN - 0927-3948

ER -